Rigel Pharmaceuticals RIGL Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 93.3%+3.7pp | 89.6%-4.3pp | 93.9%-4.6pp | 98.5%-0.7pp | |
| Operating margin | 42.6%+29.1pp | 13.5%+32.7pp | -19.2%+28.7pp | -47.9%-39.6pp | |
| Net margin | 124.7%+115pp | 9.8%+31.9pp | -22.1%+27.8pp | -49.9%-37.9pp | |
| Returns | |||||
| Return on equity | 185.9%— | —— | —— | —— | |
| Efficiency | |||||
| Asset turnover | 0.9×-0.4× | 1.3×+0.3× | 0.9×+0.1× | 0.8×-0.3× | |
| Liquidity | |||||
| Current ratio | 2.4×+0.3× | 2.1×+0.3× | 1.9×+0.1× | 1.8×-0.7× | |
| Leverage | |||||
| Debt-to-equity | 0.2×+0.1× | 0.1×— | —— | —— | |
| Net debt / EBITDA | 0.3×+2.5× | -2.1×— | —— | —— | |
| Per Share | |||||
| Book value per share | $20.78+11,078% | $0.19+111% | -$1.65-106% | -$0.80-548% | |
| Valuation | |||||
| Market capitalization | $684.39M+102% | $296.28M+17.2% | $252.84M-2.5% | $259.25M-42.8% | |
| Price / earnings | 1.9×-7.2× | 16.9×— | —— | —— | |
| Price / sales | 2.3×+0.6× | 1.7×-0.5× | 2.2×0.0× | 2.2×-0.9× | |
| Price / book | 1.7×-16.5× | 90.1×— | —— | —— | |
| EV / EBITDA | 5.7×-0.6× | 9.1×— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Rigel Pharmaceuticals's profit margins?
- Rigel Pharmaceuticals (RIGL) runs a 93.4% gross margin and a 41.6% operating margin, with a 121.5% net margin.
- Where do Rigel Pharmaceuticals's ratios come from?
- Every ratio is computed from Rigel Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
